Howard LeWine, M.D., “Quick Injection Helps Stop Epileptic Seizures,” Harvard Health Blog, Feb. 23, 2012; p. 1 “Managing Epilepsy Well Network and Selected Self-Management Programs; Putting Collective Wisdom to Work for People with Epilepsy,” Prevention Research Centers (PRC), CDC , Nov. 2016, pp.1-17 K.M.

Fiest, et al., “Prevalence and Incidence of Epilepsy, A Systematic Review and Meta-Analysis of International Studies,” NEUROLOGY 88, Jan. 17, 2017, pp.296-303 SIGMA Chemical Company Catalog (1988) E. Bechgaard et al., “Solubilization of Various Benzodiazepines for Intranasal Administration, A Pilot Study,” Pharmaceutical Development and Technology 2:293-296 (1997) A. Hussain et al. “Nasal Absorption of Propranolol in Humans,” Journal of Pharmaceutical Sciences 69:1240 (1980) S. Lau and J. Slattery, “Absorption of Diazepam and Lorazepam Following Intranasal Administration,” International Journal of Pharmaceutics, 54:171-174 (1989) M. Schols-Hendriks et al., “Absorption of Clonazepam After Intranasal and Buccal Administration,” British Journal of Clinical Pharmacology 39:449-451 (1995) 2011 Dr. Nicholas Peppas Deposition Transcript, October 24, 2019.

2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 Declaration of Dr. Sveinbjorn Gizurarson, Ph.D. J. Riss et al., “Benzodiazepines in Epilepsy: Pharmacology and Pharmacokinetics,” Acta Neurologica Scandinavica 118:69-86 (2008) D. Wermeling, U.S. Patent No. 6,610,271, issued August 26, 2003 C. Cole et al., “Community Survey of Carer’s: Individual Epilepsy Guidelines (IEG) for Rescue Medication,” Seizure 18:220-224 (2009) D. Terry et al., “Acceptance of the Use of Diazepam Rectal Gel in School and Day Care Settings,” Journal of Child Neurology 22:1135-1138 (2007) Diastat® Label (2005) “UCB announces NAYZILAM® (midazolam) nasal spray now approved by FDA to treat intermittent, stereotypic episodes of frequent seizure activity in people living with epilepsy in the U.S.,” UCB Press Release, https://www.biospace.com/article/releases/ucb-announces- nayzilam-midazolam-nasal-spray-now-approved-by-fda-to-treat- intermittent-stereotypic-episodes-of-frequent-seizure-activity-in- people-living-with-epilepsy-in-the-u-s-/ (2019) (Accessed October 31, 2019) J. French and T. Pedley, “Initial Management of Epilepsy,” New England Journal of Medicine 359:166-176 (2008) G. Corbo et al. “Measurement of Nasal Mucociliary Clearance,” Archives of Disease in Childhood 64:546-550 (1989) “How does the nose work?

The nasal mucosa,” https://www.fitonasal2act.com/how-does-the-nose-work/the-nasal- mucosa/ (Accessed November 5, 2019) N. Mygind, “Nasal Allergy,” 9 (Blackwell Scientific Publications, 1979) 2023 2024 2025 2026 2027 “Neurelis Files New Drug Application With The FDA For VALTOCO™ (Diazepam Nasal Spray), An Investigational Treatment For Pediatric, Adolescent And Adult Epilepsy Patients,” https://www.neurelis.com/neurelis-news/neurelis-files-new-drug- application-fda-valtocotm-nasal-spray-investigational-treatment- pediatric (2018) (Accessed November 1, 2019) “Neurelis Receives FDA Orphan Drug Designation for NRL-1 in the Treatment of Acute Repetitive Seizures,” https://www.neurelis.com/neurelis-news/fda-orphan-drug- designation (2015) (Accessed November 1, 2019) Affidavit of Robert Cleary (Dated November 21, 2019) [SERVED

Transcript of Telephone Conference on Feb. 11, 2020 Date: 13 February 2020 /Lorelei Westin/ Lorelei Westin, Reg. No. 52,353 Counsel for Neurelis, Inc.

Patent owner Neurelis Inc. will conduct examination by deposition of Daniel P. Wermeling.

Dr. Wermeling’s deposition will commence at 9:00AM (local time) on February 26, 2020, at the offices of Hoffmann & Baron, LLP, 4 Century Drive, Suite 300, Parsippany, NJ 07054-4606.

The deposition will be taken before a notary public or other officer authorized by law to administer oaths and will be recorded by stenographic means.

Neurelis will arrange for the reporter.

Dated: February 11, 2020 Respectfully submitted, /Lorelei Westin/ Lorelei Westin, Reg. No. 52,353 Counsel for Neurelis, Inc.

The exhibit’s probative value is substantially outweighed by its confusion of the issues to be decided, its waste of Board and Neurelis time, and the danger that it will lead to unfair prejudice if used later in the proceeding or on appeal.

The exhibit’s probative value is substantially outweighed by its confusion of the issues to be decided, its waste of Board and Neurelis time, and there is danger that it will lead to unfair prejudice if used later in the proceeding or on appeal.

FRE 901 (authentication) Aquestive failed to provide evidence sufficient to establish the exhibit is what it is purported to be.

FRE 901 (authentication) Aquestive failed to provide evidence sufficient to establish the exhibit is what it is purported to be.

upon which trial was instituted is substantially outweighed by the danger of unfair prejudice, confusing the issues, or wasting time.

US 2008/0070904, Pharmaceutical Compositions of Benzodiazepines and Method of Use Thereof, Serial No. 11/897,028, published March 20, 2008 (Jamieson) 1013 Sonne, U.S. Patent No. 6,193,985, Tocopherol Compositions For Delivery Of Biologically Active Agents, issued February 27, 2001 (Sonne) 1014 Gwozdz et al., WO 2009/120933, Pharmaceutical Solutions And Method For Solubilizing Therapeutic Agents, published October 1, 2009, International Filing Date March 27, 2009 (PCT/US2009/038518) (Gwozdz) Cartt et al., U.S. Patent Application Publication No.

21 (1992) 165-l72 (Edman II) 1033 French et al., Pharmacopeial Standards and Specifications for Bulk Drugs and Solid Oral Dosage Forms, Journal of Pharmaceutical Sciences, December 1967, Vol.

1045 Maitani, et al., Design of ocular/lacrimal and nasal systems through analysis of drug administration and absorption, Journal of Controlled Release, Volume 49, Issues 2–3, 15 December 1997, Pages 185-192.

U.S. Patent No. 9,763,876 Gudmundsdottir H, Sigurjonsdottir JF, Masson M, et al., Intranasal administration of midazolam in a cyclodextrin based formulation: bioavailability and clinical evaluation in humans.

1144 Ahmad S, Ellis J, Kamwendo H, et al. Efficacy and safety of intranasal lorazepam versus intramuscular paraldehyde for protracted convulsions in children: an open label trial.

U.S. Patent No. 9,763,876 Pursuant to 37 CFR § 42.53, Petitioner, Aquestive Therapeutics, Inc., by and through its counsel, will take the deposition of Dr. Sveinbjorn Gizurarson commencing on January 14, 2020 at 9:00 a.m. (local time), and continuing day to day until completed, at the law offices of Wilson Sonsini Goodrich & Rosati PC, 12235 El Camino Real, San Diego, CA 92130 or at such other time and location as the parties agree.

The deposition will be conducted before an officer authorized to administer oaths.

The deposition will be recorded by stenographic means.

The arrangement for the reporter will be made by counsel for Petitioner.

First Back-Up Counsel for Petitioner Aquestive Therapeutics, Inc.